Viatris/$VTRS
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Viatris
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Ticker
$VTRS
Sector
Health
Primary listing
Employees
32,000
Headquarters
Website
Viatris Metrics
BasicAdvanced
$11B
-
-$2.92
0.90
$0.48
5.11%
Price and volume
Market cap
$11B
Beta
0.9
52-week high
$13.35
52-week low
$6.85
Average daily volume
8.8M
Dividend rate
$0.48
Financial strength
Current ratio
1.37
Quick ratio
0.536
Long term debt to equity
82.153
Total debt to equity
92.947
Interest coverage (TTM)
3.02%
Profitability
EBITDA (TTM)
4,074.4
Gross margin (TTM)
40.86%
Net profit margin (TTM)
-24.57%
Operating margin (TTM)
10.72%
Effective tax rate (TTM)
7.51%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
2.26%
Return on equity (TTM)
-19.77%
Valuation
Price to revenue (TTM)
0.79
Price to book
0.71
Price to tangible book (TTM)
-1.47
Dividend yield (TTM)
5.11%
Forward dividend yield
5.11%
Growth
Revenue change (TTM)
-7.37%
Earnings per share change (TTM)
440.37%
3-year revenue growth (CAGR)
-6.35%
10-year revenue growth (CAGR)
5.32%
3-year earnings per share growth (CAGR)
66.85%
10-year earnings per share growth (CAGR)
3.52%
3-year dividend per share growth (CAGR)
-20.07%
What the Analysts think about Viatris
Analyst ratings (Buy, Hold, Sell) for Viatris stock.
Bulls say / Bears say
Viatris has initiated a strategic review to streamline costs and position the organization for future growth, indicating proactive management aimed at enhancing operational efficiency. (GuruFocus)
The company has returned approximately $450 million to shareholders, including $300 million through share repurchases, demonstrating a commitment to shareholder value. (GuruFocus)
Viatris reported positive data for Phase 3 studies of novel fast-acting meloxicam for moderate to severe acute pain, highlighting its potential as a non-opioid treatment option. (GuruFocus)
Viatris faces a class action lawsuit alleging that the company misled investors regarding a failed inspection at its Indore, India facility, potentially leading to financial liabilities. (GuruFocus)
The company reported a non-cash goodwill impairment charge of $2.9 billion due to a decline in share price and increased business risk, reflecting potential challenges in asset valuation. (GuruFocus)
Viatris' North American business decreased 8% compared to the prior year, impacted by the Indore facility issues and competition on select generic products, indicating market challenges. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Viatris Financial Performance
Revenues and expenses
Viatris Earnings Performance
Company profitability
Viatris News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Aug22
Viatris
Dividend·Ex-dividend
Sept15
Viatris
Dividend·Payment
$0.12Per share
FAQs
What’s the current market cap for Viatris stock?
Viatris (VTRS) has a market cap of $11B as of August 11, 2025.
What is the P/E ratio for Viatris stock?
The price to earnings (P/E) ratio for Viatris (VTRS) stock is 0 as of August 11, 2025.
Does Viatris stock pay dividends?
Yes, the Viatris (VTRS) stock pays dividends to shareholders. As of August 11, 2025, the dividend rate is $0.48 and the yield is 5.11%. Viatris has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Viatris dividend payment date?
The next Viatris (VTRS) dividend payment is scheduled for September 15, 2025.
What is the beta indicator for Viatris?
Viatris (VTRS) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.